Andrew Hill
Research Mentor: Orsolya Lautner-Csorba
Mentor Department: Urop Ecls Student, Medicine
Author(s): Andrew Hill, Anthony Cinetti, Ryan Kauffman, Neenor Razoky, Jianfeng Wu, Mark E. Meyerhoff, Gabe Owens, Alvaro Rojas-Peña, Orsolya Lautner-Csorba
Session: Session 3 (11:00 AM – 11:50 AM)
Presentation Type: Poster 20
Abstract
Background: S-nitroso-1-adamantanethiol (SNAT) is a potent nitric oxide (NO) donor with promising applications for catheter impregnation, enabling surface NO release that bears both antithrombotic and antimicrobial properties. These effects are critical for preventing thrombus formation and central-line associated bloodstream infections (CLABSIs), which pose significant risks especially to pediatric patients undergoing catheterization. This study evaluates a 5 Fr intravenous catheter (IVC) impregnated with SNAT to assess mechanical integrity, NO release, and antimicrobial efficacy prior to ovine in vivo testing. Methods: Texture analysis was performed to characterize mechanical integrity of catheters after treatment using Young’s modulus. NO release analysis was performed on 2000 mg/mL impregnated SNAT (iSNAT2000) over several days to demonstrate sustained NO release. To assess the bactericidal efficacy of iSNAT2000 IVCs, samples were tested against Pseudomonas aeruginosa and Staphylococcus aureus strains. The planktonic cell counts (CFU/mL) were measured at various time points over 24 hours. Additionally, the degree of formed biofilm (CFU/cm2) on the surface of the iSNAT2000 IVCs was evaluated over 14 days using a CDC biofilm reactor. Results: The tensile strength of iSNAT2000 IVCs was sufficiently maintained above a minimum of 50% Young’s modulus compared to control. The iSNAT2000 IVCs achieved a sustained NO release of 10 days. In antimicrobial testing, iSNAT2000 samples showed a 3-log reduction in planktonic cell counts compared to the control. iSNAT2000 samples also showed strong anti-biofilm effects with 3-log reduction of biofilm density by day 14 compared to control. Conclusion: These findings confirm the significant antimicrobial effect and prolonged NO release of iSNAT2000 IVCs, providing valuable information for a future in vivo study. It is hoped that this study and future studies will establish iSNAT2000 IVCs as a strong candidate for preventing clot formation and serious infection, especially in the most vulnerable pediatric population.
